INCY - Incyte Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
85.67
+0.05 (+0.06%)
At close: 4:00PM EDT

85.67 0.00 (0.00%)
After hours: 6:35PM EDT

Stock chart is not supported by your current browser
Previous Close85.62
Open86.12
Bid85.65 x 800
Ask86.45 x 1000
Day's Range85.21 - 86.35
52 Week Range57.00 - 89.75
Volume662,752
Avg. Volume1,550,188
Market Cap18.337B
Beta (3Y Monthly)1.17
PE Ratio (TTM)167.98
EPS (TTM)0.51
Earnings DateApr 29, 2019 - May 3, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est89.33
Trade prices are not sourced from all markets
  • Markit12 hours ago

    See what the IHS Markit Score report has to say about Incyte Corp.

    Incyte Corp NASDAQ/NGS:INCYView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for INCY with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting INCY. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding INCY are favorable, with net inflows of $12.50 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Why Is Incyte (INCY) Up 1.7% Since Last Earnings Report?
    Zacks3 days ago

    Why Is Incyte (INCY) Up 1.7% Since Last Earnings Report?

    Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Agenus Inc (AGEN) Q4 2018 Earnings Conference Call Transcript
    Motley Fool5 days ago

    Agenus Inc (AGEN) Q4 2018 Earnings Conference Call Transcript

    AGEN earnings call for the period ending December 31, 2018.

  • Zacks.com featured expert Kevin Matras highlights: Incyte, AMC Entertainment, Covanta and U.S. Silica
    Zacks5 days ago

    Zacks.com featured expert Kevin Matras highlights: Incyte, AMC Entertainment, Covanta and U.S. Silica

    Zacks.com featured expert Kevin Matras highlights: Incyte, AMC Entertainment, Covanta and U.S. Silica

  • 10 Stocks Powering S&P 500 ETF in the 10-Year Bull Run
    Zacks6 days ago

    10 Stocks Powering S&P 500 ETF in the 10-Year Bull Run

    Though most of the stocks in the S&P 500 ETF have delivered astounding returns during the decade, a few were the real stars, skyrocketing more than 2000%.

  • 4 Toxic Stocks to Abandon or Sell Short for Solid Gains
    Zacks6 days ago

    4 Toxic Stocks to Abandon or Sell Short for Solid Gains

    Overhyped toxic stocks are usually susceptible to external shocks and burdened with huge amount of debt.

  • Why Incyte Corporation (NASDAQ:INCY) Is A Financially Healthy Company
    Simply Wall St.11 days ago

    Why Incyte Corporation (NASDAQ:INCY) Is A Financially Healthy Company

    Incyte Corporation (NASDAQ:INCY), a large-cap worth US$18b, comes to mind for investors seeking a strong and reliable stock investment. Most investors favour these big stocks due to their strong balanceRead More...

  • Pullback Strategies: 10 Stocks That Could Fall the Fastest
    Investopedia14 days ago

    Pullback Strategies: 10 Stocks That Could Fall the Fastest

    These stocks are heavily owned by high-turnover hedge funds, and thus are likely to face severe selling pressure once these funds turn bearish.

  • Merck Gets CHMP Nod for Six-Week Dosing Option of Keytruda
    Zacks14 days ago

    Merck Gets CHMP Nod for Six-Week Dosing Option of Keytruda

    Merck (MRK) gets CHMP recommendation for a six-week dosing schedule of Keytruda across all current monotherapy indications.

  • MoneyShow15 days ago

    Incyte- Insights into Small Molecule Drugs

    Incyte (INCY) develops small molecule drugs to treat cancer and inflammatory diseases, explains Mike Cintolo, a leading growth stock expert and editor of Cabot Top Ten Trader.

  • GlobeNewswire19 days ago

    New Research Coverage Highlights Nasdaq, Constellation Brands, Incyte, IMAX, HNI, and Frank's International N.V — Consolidated Revenues, Company Growth, and Expectations for 2019

    NEW YORK, March 01, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wire19 days ago

    Incyte Joins Patient Organizations Worldwide in Recognizing Rare Disease Day 2019

    The MPN community is encouraged to participate in awareness initiatives and access new resources at VoicesofMPN.com. Incyte Corporation (INCY) announced today that it has again joined with the National Organization for Rare Disorders (NORD), the European Organizations for Rare Diseases and other health organizations and advocates in recognizing Rare Disease Day 2019 – an initiative that raises awareness of rare diseases and the impact they can have on the lives of patients and caregivers. In honor of the day, Incyte is supporting several efforts intended to educate and increase awareness of myeloproliferative neoplasms (MPNs), a group of rare, chronic blood cancers.

  • Business Wire19 days ago

    Data from Incyte’s Cancer Research Portfolio to be Featured in Seven Abstracts at the AACR Annual Meeting 2019

    Incyte Corporation announces that seven abstracts showcasing data from its cancer research portfolio will be presented at the upcoming American Association for Cancer Research Annual Meeting 2019.

  • Zacks.com featured expert Kevin Matras highlights: First Majestic Silver, Incyte, Covanta and U.S. Silica
    Zacks20 days ago

    Zacks.com featured expert Kevin Matras highlights: First Majestic Silver, Incyte, Covanta and U.S. Silica

    Zacks.com featured expert Kevin Matras highlights: First Majestic Silver, Incyte, Covanta and U.S. Silica

  • InvestorPlace21 days ago

    3 Big Stock Charts for Wednesday: Cabot Oil & Gas, Incyte and Sempra Energy

    Much like Monday, on Tuesday, traders weren't quite sure which direction they wanted to go. And, when all was said and done, they didn't really go anywhere. The S&P 500 ended yesterday's action 0.07% lower than Monday's close, and more or less in the middle of the day's high/low range.That doesn't mean there weren't big movers though. Holding the market back in a big way was Home Depot (NYSE:HD). Shares of the home improvement retailer fell nearly 1% in response to a fourth quarter earnings miss and lackluster profit outlook for 2019.At the other end of the spectrum, China's upscale electric carmaker Nio (NYSE:NIO) rallied 8.6% following Monday's 60 Minutes interview with CEO William Li. For some investors, it was the first they'd ever heard of the company, driving a sudden wave of interest. Etsy (NASDAQ:ETSY) fared even better though, up 16.3% following a fourth-quarter earnings and revenue beat. There was just more bearish volume than bullish volume on Tuesday, and more advancers than decliners.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAs Wednesday's action gets going, it's the stock charts of Cabot Oil & Gas (NYSE:COG), Incyte (NASDAQ:INCY) and Sempra Energy (NYSE:SRE) that offer the most trading potential. Here's why, and what to look for. Sempra Energy (SRE)At first glance Sempra Energy is little more than a volatile mess. But, a closer inspection reveals there's actually a relatively organized effort underway. * 10 Blue-Chip Stocks to Lead the Market One more good shove and months worth of consolidation could readily turn into a nice breakout thrust. Click to Enlarge • Though apparent on the daily chart, it's better appreciated on the weekly chart that SRE shares are being ushered higher by a set of parallel support and resistance lines, plotted in blue. Sempra shares just pushed off the lower edge of the range near the end of last year.• In the meantime, clear resistance has formed around $120, plotted with a yellow dashed line on both stock charts.• While we've seen bullish thrusts fail before, this one is different. This time, the pullback seen earlier this month was halted and reversed at a convergence of several key moving average lines. It's a sign that the bulls have finally drawn a line in the sand. Cabot Oil & Gas (COG)If Cabot Oil & Gas rings a bell, there's a reason. It was one of the stock charts featured back on Feb. 20, after several weeks' worth of volatility finally began to make discernible progress. While more up and down was in the cards, the undertow had turned bullish.COG shares promptly pulled back the very next day, calling the thesis into question. But since then, the uptrend has been rekindled after COG found support right where it needed to. Click to Enlarge • Last week's pullback stopped at the 200-day moving average line, plotted in white, and was firmly reversed.• While still volatile, notice the 200-day moving average as well as the gray 100-day moving average line are both sloped upward now, confirming the overall trend is bullish.• Zooming out to the weekly chart we can see the slow, U-shaped reversal that has been taking shape since the middle of last year, aided by a long-standing support line.• Though the tide is bullish here, Cabot Oil & Gas still faces minor resistance at $25.20 and major resistance right around $26. Incyte (INCY)Finally, Incyte has been featured several times since the middle of last year as a breakout candidate. It didn't happen in earnest until January though, and it ultimately took a bearish headfake to set the move up. And even then, there was doubt.The breakout thrust has really firmed up over the course of the past month, however, and is worth a refreshed look. While some profit-taking is likely to be in the cards, the recent gain has developed enough cushion to make a small setback not only palatable, but productive. Click to Enlarge • The big line in the sand was at $74.90, plotted in red on both stock charts. Shares punched through that ceiling in early January, and have put some distance between them and it in the meantime.• While the divergence sends a statement, it's also clear that even just the move since early January has brought INCY to the brink of being overbought. A dip that burns off that froth would actually be bullish, in the bigger picture.• Any pullback would ideally (and probably would be) stopped and reversed either the purple 50-day moving average line or the gray 100-day average.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Consumer Stocks to Buy and Hold for Years * 4 China Stocks Soaring on Trade Hopes * 3 Esports Stocks to Benefit From the Boom Compare Brokers The post 3 Big Stock Charts for Wednesday: Cabot Oil & Gas, Incyte and Sempra Energy appeared first on InvestorPlace.

  • Macrogenics Inc (MGNX) Q4 2018 Earnings Conference Call Transcript
    Motley Fool21 days ago

    Macrogenics Inc (MGNX) Q4 2018 Earnings Conference Call Transcript

    MGNX earnings call for the period ending December 31, 2018.

  • 4 Toxic Stocks to Discard or Sell Short for Solid Gains
    Zacks21 days ago

    4 Toxic Stocks to Discard or Sell Short for Solid Gains

    Overhyped toxic stocks are usually susceptible to external shocks and loaded with huge amount of debt.

  • Looking For Growth? Take A Look At These Biotechnology Stocks
    Investor's Business Daily26 days ago

    Looking For Growth? Take A Look At These Biotechnology Stocks

    The best biotech companies to invest in tend to have a commonality: A strong streak of earnings growth.

  • Merck Gets Priority Review for Keytruda in Third-Line SCLC
    Zacks26 days ago

    Merck Gets Priority Review for Keytruda in Third-Line SCLC

    Merck's (MRK) sBLA looking for approval of Keytruda monotherapy for the third-line treatment of small cell lung cancer, a difficult-to-treat cancer, gets FDA's priority review.

  • 6 Companies With 20% Or More Earnings Growth
    Investopedia27 days ago

    6 Companies With 20% Or More Earnings Growth

    Investors concerned about holding shares of companies with slowing profit growth might look at Goldman Sachs' basket of stocks with earnings growth forecasts of 20% or higher in 2019. The firm’s list includes companies across industries such as Wellcare Health Plans (WCG), Incyte Corp.

  • Merck's Keytruda Fails to Meet Endpoint in Liver Cancer Study
    Zacks27 days ago

    Merck's Keytruda Fails to Meet Endpoint in Liver Cancer Study

    Merck's (MRK) Keytruda fails a phase III study in second-line advanced hepatocellular carcinoma (HCC). It gets FDA approval for the adjuvant treatment of patients with high-risk stage III melanoma.

  • Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why
    Zacks28 days ago

    Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why

    Merck's (MRK) stock is up 45.2% in the past year. Here are reasons for the same.

  • Business Wire28 days ago

    Incyte to Present at Upcoming Investor Conferences

    Incyte Corporation announced today that it will present at the following investor conferences during the month of March:

  • Merck Gets Priority Review for Keytruda Combo in Kidney Cancer
    Zacks29 days ago

    Merck Gets Priority Review for Keytruda Combo in Kidney Cancer

    Merck's (MRK) sBLA looking for approval of Keytruda plus Pfizer's Inlyta for the first-line treatment of the most common type of kidney cancer gets FDA's priority review.